Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 2 clinical trial of DARE-HPV

Next Previous
Trial Profile

A phase 2 clinical trial of DARE-HPV

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 07 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lopinavir/ritonavir (Primary)
  • Indications Cervical intraepithelial neoplasia; Human papillomavirus infections
  • Focus Therapeutic Use

Most Recent Events

  • 31 Mar 2025 According to a Dare Bioscience media release, the company announced that they are conducting activities necessary to enable submission of an IND application to the FDA for a Phase 2, randomized, placebo-controlled, double-blind clinical study of DARE-HPV for clearance of high-risk HPV infection in women.
  • 14 Feb 2025 New trial record
  • 06 Feb 2025 According to a Dare Bioscience media release, the company announced that it is eligible to Dare is eligible to receive up to a total of approximately 2 million USD in grant funding for its DARE-HPV program based on the grant application it submitted. A grant in the amount of 1 million USD has been awarded for the 2025 project year, and another 1 million has been recommended for a subsequent project year by National Institute of Allergy and Infectious Diseases (NIAID).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top